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ABSTRACT
Objectives: To compare the prevalence of use of
potentially inappropriate medicines (PIMs) between
older patients living in their own homes versus those
living in nursing or residential homes, and to test the
association between exposure to PIMs and mortality.
Design: Cohort study stratified by place of residence.
Setting: Tayside, Scotland.
Participants: All people aged between 66 and 99 years
who were resident or died in Tayside from 2005 to
2006.
Main outcome measures: The exposure variable was
PIM use as defined by Beers’ Criteria. All cause
mortality was the main outcome measure.
Results: 70 299 people were enrolled in the cohort of
whom 96% were exposed to any medicine and 31%
received a PIM. Place of residence was not associated
with overall risk of receiving PIMs, adjusted OR 0.94,
95% CI 0.87 to 1.01. Exposure to five of the PIMs
(including long-acting benzodiazepines) was
significantly higher in nursing homes whereas
exposure to five other PIMs (including amitriptyline and
NSAIDs) was significantly lower. Exposure to PIMs was
similar (20e46%) across all 71 general practices in
Tayside and was not associated with increased risk of
mortality after adjustment for age, gender and
polypharmacy (adjusted OR 0.98, 95% CI 0.92 to 1.05).
Conclusions: The authors question the validity of the
full list of PIMs as an indicator of safety of medicines
in older people because one-third of the population is
exposed with little practice variation and no significant
impact on mortality. Future studies should focus on
management of a shorter list of genuinely high-risk
medicines.
INTRODUCTION
Patients aged over 65 have the highest
burden of illness, and therefore require
drug-based interventions to prevent or treat
multiple medical conditions.1 Unfortunately,
older people may be prescribed unnecessary
drugs; drugs that are contraindicated for
their age group; or wrong dosages for their
age.2 Such medication is characterised as
potentially inappropriate medicines (PIMs)
and is a concern for several reasons. Patients
may receive an array of different drugs, many
from different drug classes that increase the
risk of iatrogenic harm, particularly in
patients with multiple morbidities.3e5 A
further consequence of PIMs is that an
unrecognised side effect from a PIM drug
may be mistaken for a new symptom for
which another drug is initiated, leading to
a ‘prescribing cascade’ and further iatrogenic
harm.6
A particularly vulnerable group are patients
in long-term institutional care (nursing and
residential homes) because of their higher
level of physical and mental impairment
requiring drug treatment. Previous work
shows that nursing home residents receive up
to four times as many prescription items as
people living in their own home and take, on
average, five or more medicines.7e9 General
practitioners (GPs) are responsible for the
delivery of medical care to older patients in
nursing homes. In the last 20 years there has
been anxiety that ‘downsizing’ of NHS
provision has increased demand on GPs in
a group of patients with high morbidity and
disability9e11 and that the delivery of care to
nursing homes has become inconsistent and
idiosyncratic.3
Particular concerns are raised about the
risks of PIMs and medication error for
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patients in long-term residential care as there is evidence
that poor monitoring of disease and prescription of
unnecessary and inappropriate medication is more likely
to occur in these patients, even after adjusting for
multiple morbidity.12 13
In this observational study in Tayside, Scotland, the
authors investigated whether there were differences in
PIMs (globally and across different classes of PIM drugs)
between older people living in their own home
compared with people living in nursing or residential
homes. They also assessed whether receiving a PIM was
associated with an increased risk of death.
METHODS
Identification of study cohort
The authors carried out this study using anonymised
healthcare data for the population of Tayside, Scotland.
These data are managed by the Health Informatics
Centre (HIC) of the University of Dundee. HIC main-
tains internationally recognised record-linkage databases
for approximately 400 000 individuals in 74 general
practices. It links patient data by means of a community
health identifier (CHI) allocated to all patients when
they register with a GP. The CHI number allows indi-
vidual patient data from separate databases (dispensed
prescribing, hospitalisation, laboratory results and death
certification) to be linked.14
All patients aged between 66 and 99 years and resi-
dent in Tayside on 1 January 2005 were identified.
Patients aged 100 years or older and patients who
moved out of the area during the study period
(2005e2006) were excluded from the study. To deter-
mine whether a patient lived at home or in a care home,
a list of addresses was compiled for all nursing homes,
residential care homes and mixed care homes in
Tayside. Care home lists were obtained from the rele-
vant councils and hospitals in the area, and cross-
checked with the local telephone directory to ensure
that all homes had been identified. Care home
addresses were compared with electronic patient
addresses held by NHS Tayside (as of May 2005). If
a patient’s address did not match one of the addresses
of the care homes, they were classed as living in their
own home. This was carried out using a computer
algorithm, but 377 addresses were manually checked
where there was still uncertainty.
Data from all prescriptions encashed in Tayside during
the 2-year study period (2005e2006) for each patient
were obtained (approximately 5 million). The informa-
tion available included CHI number, the drug name,
prescription date and British National Formulary code.
Demographic data including patients’ age and sex were
obtained from the master CHI file.
Measurement of potentially inappropriate medicines
The authors used the updated Beers’ Criteria to identify
PIMs.15 These refer to a set of drugs and contexts that
was devised in the United States in relation to PIMs in
older people. They are the most widely recognised
explicit process measures for inappropriate medicines.
Although approximately half of the drugs on the Beers
list are not available in Europe, use of these criteria has
the advantage of enabling international comparison.16
Additionally, Beers’ Criteria PIMs have been categorised
and labelled by potential adverse outcomes of either low
or high severity. For the purposes of this study, Beers’
Criteria drugs were adapted so that drugs/drug names
not used in the UK were replaced with the UK equiva-
lent. A pharmacist was involved throughout this process
and authorised any modifications that were made.
Prescribing records were examined and prescriptions for
drugs included in the Beers’ Criteria were extracted. The
numbers of prescriptions per patient were then calcu-
lated, along with the total number of different drug
classes, grouped by the British National Formulary, as
a proxy for multiple morbidities.
Four of the Beers’ Criteria drugs included in the anal-
yses were dependent on the dose of the prescribed
medication. Directions regarding dose information were
only available for registered diabetic patients in Tayside.
The total numbers of these patients receiving the relevant
drugs were retrieved. The proportion of patients that
exceeded the recommended daily dose (Beers’ Criteria)
was calculated for the subset of patients whose dose
information was available. An estimate of the proportion
of patients in the total population who would exceed the
criteria was then extrapolated from this subset of patients.
The number of PIMs prescribed to each patient was also
calculated. Dose related criteria for individual patients
were only counted if thedose informationwas present and
exceeded the recommended daily dose.
Statistical methods
Descriptive statistics of individuals living at home and in
care along with the proportion receiving Beers’ Criteria
PIMs in these respective settings are described.
The association between place of residence and
number of PIMs received using proportional odds
models, both unadjusted and then adjusted for age, sex
and comorbidity was assessed. The reported ORs relate
to the likelihood of having a worse outcome (number of
PIMs) across the range of possible categories. The
authors also assessed the independent effects of demo-
graphic variables, number of drugs prescribed and place
of residence in terms of probability of receiving a Beers’
Criteria PIM.
In addition, individuals were grouped by an anony-
mous code representing their practice so that variability
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by practice of the proportion of elderly patients who had
received one or more PIM was described. To examine
the effect of clustering, the logistic regression model was
repeated with the patients clustered by anonymous
practice code, with a random effects model fitted.
Descriptive statistics and associations were assessed in
terms of cumulative number of Beers’ PIMs and place of
residence by means of ordinal logistic regression. Overall
and specific types of Beers’ Criteria PIMs in relation to
place of residence were also assessed using logistic
regression analysis and adjusting for age, sex and poly-
pharmacy. Last, logistic regression analysis was performed
to investigate the impact of receiving at least one Beers’
Criteria PIMonall causemortality after adjusting for place
of residence, age, sex and polypharmacy.
RESULTS
Descriptive statistics
A total of 70 299 patients aged 66e99 years were resident
in Tayside, Scotland, between 2005 and 2006. Of this
4557 (6.5%) were living in care, 2230 (3.2%) in nursing
homes, 1799 (2.6%) in residential care and 528 (0.8%)
in mixed care homes. Patients living in care were almost
five times more likely to die, were predominantly female
and were significantly older than patients living at home.
Over the course of the 2-year period studied, patients
received a median of 55 prescriptions (IQR 26e95), with
6% receiving no prescriptions, 27% receiving medica-
tions for between one and five different drug classes and
67% receiving medications from six or more drug
classes. Patients living in care received almost twice as
many prescriptions as patients still living at home and
received a higher number of prescriptions from
different drug classes (table 1).
Beers’ Criteria drugs overall
The majority of Beers’ Criteria drugs (n¼19, 58%) were
deemed not to be relevant for further analysis either
because the drug was not prescribed in Tayside or was
prescribed to very few patients (<0.5% of study popu-
lation). These drugs were excluded from further anal-
yses and are listed separately (web table 1).
When prescription of the remaining 14 Beers’ Criteria
drugs were assessed, patients living in care homes
received more PIMs with a mean of 0.49 prescriptions,
compared with a mean of 0.41 prescriptions for patients
living at home (p<0.001); in absolute terms 1690
(37.1%) patients in care home received a PIM during
the 2-year period of observation compared with 20 304
(30.9%) living at home (table 2). After adjustment for
age, sex and polypharmacy, patients were more likely to
receive at least one PIM if they were younger, female and
had higher polypharmacy. However, place of residence
was not independently associated with likelihood of
receiving PIM when measured as a binary variable (none
vs. any PIM) (table 3).
Practice level prescribing of Beers’ Criteria drugs
A reasonably consistent pattern emerged across the 71
Tayside practices, with 20e46% of their practice popu-
lation aged >65 years receiving at least one Beers’
Criteria PIM during the 2 years of the study (figure 1).
Drug-specific Beers’ Criteria
Overall, 37.1% of patients in care received a Beers’
Criteria PIM compared with 30.9% at home. Amitripty-
line (7.6%), ferrous sulphate (7.1%) and long-acting
benzodiazepines (6.7%) were the three most commonly
prescribed PIMs among patients aged 65e99 years in
Tayside (table 4). The authors identified statistically
significant differences by place of residence for certain
drug-specific PIMs. Psychotropic PIMs such as long-
acting benzodiazepines, and fluoxetine as well as muscle
relaxants, (methocarbomol and oxybutynin) nitro-
furantoin and dipyridamole were prescribed more
frequently to patients living in care while amitriptyline,
nonsteroidal anti-inflammatory drugs (NSAIDs),
Table 1 Descriptive statistics of patients aged 65 years and older living in Tayside, Scotland, 2005e2006
At home In care
Number of patients (%) 65742 (93.5) 4557 (6.5)
Mean age (SD) 75.2 (6.8) 84.5 (7.5)
Age categories, n (%)
66e70 20034 (30) 239 (5)
71e80 31148 (47) 1065 (23)
81e90 12934 (20) 2176 (48)
91e99 1626 (2) 1077 (24)
Female sex, n (%) 37497 (57.0) 3296 (72.3)
No. of deaths (%) 5321 (8.1) 1790 (39.3)
Mean no. of prescriptions (95% CI) 66.7 (66.28 to 67.22) 113 (110.37 to 115.56)
Mean no. of drug classes (95% CI) 8.8 (8.73 to 8.82) 11.6 (11.39 to 11.77)
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gastrointestinal antispasmodics doxazosin and cimeti-
dine were prescribed more often to patients living at
home (table 4). The ORs generally reduced after
adjusting for other risk factors, but independent effects
of place of residence were still evident.
Beers’ Criteria and all cause mortality
After adjusting for place of residence, age, sex and
polypharmacy by means of logistic regression, receiving
at least one Beers’ Criteria PIM did not lead to an
increased risk of mortality, with an OR of 0.98 (95% CI
0.92 to 1.05). As anticipated, patients living in care, older
patients and patients with additional polypharmacy were
more likely to die, with ORs of 3.48 (95% CI 3.24
to 3.75), 1.10 (95% CI 1.10 to 1.10) and 1.03 (95%
CI 1.02 to 1.03), respectively. Women were less likely
to die compared with men, with an OR of 0.63 (95%
CI 0.60 to 0.67).
DISCUSSION
Statement of principal findings
This study shows that use of prescription medicines is
high in older patients in Tayside, who receive on
average 70 prescriptions over 2 years, with almost 70%
of patients receiving prescriptions from six or more
drug classes. Beers’ Criteria PIMs occur for over a third
of the >65 population; and this level of PIM is consis-
tent across all Tayside practices (figure 1). Patients are
at increased risk for receiving a Beers’ Criteria PIM
if they are younger, female and have increased
polypharmacy. No evidence was found to suggest that
place of residence influences the overall risk of
receiving a Beers’ Criteria PIM, however cumulative risk
of PIMs is associated with place of residence (table 2).
A pattern emerges in relation to drug-specific PIMs
with psychotropic drugs being more commonly
prescribed in residential/nursing home care settings
(aside from amitriptyline). All cause mortality is not
independently associated with the 13 UK relevant
Beers’ PIMs.
Strengths and weaknesses of the study
The strengths of this study are that it allows a complete
assessment of PIM in a defined geographical population
enhancing external validity, and describes PIM at the
individual and practice level. It also helps in assessing
the type of PIM according to drug class in relation to
place of residence. Record-linkage enables assessment of
PIM in relation to all-cause mortality.
Table 2 Number (percentage) of patients receiving prescriptions of PIMs by place of residence
Number of Beers’ drugs At home, n (%) In care, n (%)
OR (95% CI)
Unadjusted Adjusted*
0 45438 (69.1) 2, 867 (62.9) 1.0 1.0
1 15225 (23.2) 1236 (27.1) 0.81 (0.79 to 0.82) 1.22 (1.02 to 1.41)
2 3943 (6.0) 364 (8.0) 2.48 (2.45 to 2.51) 3.25 (3.06 to 3.45)
3 916 (1.4) 76 (1.7) 4.05 (4.00 to 4.11) 5.03 (4.83 to 5.23)
4+ 220 (0.3) 14 (0.3) 5.72 (5.59 to 5.85) 6.81 (6.58 to 7.04)
*Cumulative Beers’ PIM and place of residence assessed by means of ordinal logistic regression, adjusting for age, gender and polypharmcay.
PIM, potentially inappropriate medicine.
Table 3 Relationship between receiving a PIM with demographic variables, number of drugs prescribed and place of
residence
Explanatory variable
OR (95% CI)
Unadjusted Adjusted*
Age categories, n (%)
66e70 1.0 1.0
71e80 1.16 (1.12 to 1.21) 0.91 (0.88 to 0.95)
81e90 1.18 (1.13 to 1.24) 0.76 (0.72 to 0.80)
91e99 0.98 (0.89 to 1.07) 0.65 (0.58 to 0.72)
Male 1.0 1.0
Female 1.37 (1.33 to 1.42) 1.22 (1.17 to 1.26)
Polypharmacy (no. of drug classes) 1.19 (1.18 to 1.19) 1.19 (1.19 to 1.19)
At home 1.0 1.0
In care 1.32 (1.24 to 1.40) 0.94 (0.87 to 1.01)
*Mutually adjusted for age, gender, polypharmacy and place of residence.
PIM, potentially inappropriate medicine.
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There are some shortcomings to this study. The
encashed prescribing information only had completed
dosage instructions for the population members who
were diabetic. For Beers’ Criteria PIMs, which required
dosage information, the reported prevalence was
measured in diabetic patients where dosing information
was available and then the number of all patients esti-
mated by using this prevalence and the known number
of patients receiving that medication. For the remainder
of the analysis if dosage information was unknown
relating to an individual Beers’ Criterion it was assumed
the patient did not fail that criterion, so estimates of PIM
in relation to dosing are necessarily conservative. In
terms of prescribing responsibility, all drugs were
prescribed in the community by GPs. However,
a proportion of drugs will have been initiated by hospital
physicians, and it is not possible to know which drugs
were hospital initiated and continued by GPs.
Adjustment for socio-economic status is not made as
patients in care homes would not have been accurately
characterised. The last address for patients prior to
moving into a nursing or residential care home would be
required to allow for accurate measurement of socio-
economic status and this information was not available.
As has been observed in studies of PIM in the UK, Beers’
Criteria do not apply to the majority of drugs used in UK
settings (not available or low level of usage). However,
use of these criteria is the most widely used explicit
process measure of PIM and does enable between-
country comparison.16 The authors did not have access
to morbidity diagnoses and used number of medications
as a proxy measure. Last, as patients were followed-up for
a 2-year period only, the lack of association between PIM
and all cause mortality should be treated with caution.
Context of other studies
The findings from this study are broadly consistent with
previous research into PIMs in elderly people,
confirming a high prevalence, despite the recognition
and ongoing concerns about the iatrogenic harms asso-
ciated with PIMs.2 16 In addition, specific drugs that are
known to increase risk in older patients continue to be
prescribed at relatively high rates, for instance, amitrip-
tyline and long-acting benzodiazepines.17 18 This study
also suggests that younger age, being female and poly-
pharmacy were the biggest predictors for receiving PIMs.
These results are partly consistent (association of PIMs
with female gender and polypharmacy) and partly at
Table 4 Beers’ Criteria for specific PIMs by place of residence
Criteria At home % In care %
OR (95% CI) Severity
ratingUnadjusted Adjusted*
Long-acting benzodiazepines 6.36 11.13 1.85 (1.68 to 2.04) 1.62 (1.45 to 1.81)z High
Nitrofurantoin 2.46 5.84 2.46 (2.15 to 2.81) 1.52 (1.30 to 1.76)z High
Fluoxetine 2.10 4.83 2.37 (2.05 to 2.74) 2.25 (1.91 to 2.65)z High
Muscle relaxants 1.69 3.84 2.32 (1.97 to 2.73) 1.42 (1.19 to 1.70)z High
Dipyridamole 1.47 3.75 2.61 (2.21 to 3.08) 1.74 (1.45 to 2.09)z Low
Amitriptyline 7.76 5.99 0.76 (0.67 to 0.86) 0.59 (0.51 to 0.67)x High
NSAIDs 3.92 1.56 0.39 (0.31 to 0.49) 0.42 (0.33 to 0.54)x High
Gastrointestinal antispasmodic 1.06 0.92 0.87 (0.63 to 1.18) 0.70 (0.51 to 0.98)x High
Doxasozin 5.66 2.15 0.37 (0.30 to 0.49) 0.29 (0.24 to 0.36)x Low
Cimetidine 0.84 0.48 0.57 (0.37 to 0.88) 0.48 (0.31 to 0.75)x Low
Ferrous sulphatey >325 mg/d 6.61 13.93 1.32 (1.02 to 1.70) 0.76 (0.58 to 1.01) Low
Anticholinergics/antihistamines 3.34 4.7 1.42 (1.23 to 1.64) 1.05 (0.90 to 1.23) High
Digoxiny >125 mg/day 1.60 2.65 1.05 (0.62 to 1.77) 0.74 (0.43 to 1.29) Low
Amiodarone 0.68 0.88 1.29 (0.93 to 1.79) 0.76 (0.54 to 1.08) High
*Age, sex and polypharmacy were adjusted for in all analyses.
yResults extrapolated from patients registered with diabetes.
zSignificantly higher PIM in ‘in care’ patients.
xSignificantly higher PIM in ‘at home’ patients.
NSAID, nonsteroidal anti-inflammatory drug; PIM, potentially inappropriate medicine.
Figure 1 Practice level prescribing of Beers’ Criteria drugs.
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odds (not associated with advancing age) with a recent
English study.19 The most consistent finding relates to
polypharmacy, which in itself is likely to be a marker for
multi-morbidity.
The study findings show no association between Beers’
Criteria and mortality, which is in contrast to the find-
ings of two earlier papers.20 21 However both of these
papers were in populations of nursing home residents
only and one had a significantly smaller population. The
present study adjusted for place of residence along with
polypharmacy, gender and age and found no effect.
Last, the findings concerning prescription of long-
acting benzodiazepines have been a consistent cause for
concern in terms of patients in care homes and remains
one of the most common PIMs with a significantly
higher prevalence in care home patients (table 3).
A recent review of appropriate prescribing in older
patients suggested that the criteria for medicine safety
should ‘constitute a floor of quality below which no
patient should go’. From the study data it can be seen
that every practice is exposing a minimum of 20% of
patients at risk to these medicines so there is clearly
unanimous disagreement that the Beers’ Criteria do
constitute a floor of quality.16 Controversy exists over
some of the medications considered by Beers to be
inappropriate, the latest update suggests that cost
containment has been a major driver, and it has also
been argued that the Beers’ Criteria do not address all
aspects of PIMs in older people.18 22 23 Despite this, the
Beers’ Criteria remain one of the more commonly used
tools for assessing PIMs in older patients although
whether or not the criteria act as good indicators for
adverse drug events remains unclear. Definitions
concerning medication error have also been described,
with categorisation into serious, life-threatening or fatal
events.24 Modification of these types of criteria has been
used successfully in the measurement of care in
nursing/residential homes in the UK.13 Finally, more
research is needed from European-based PIP criteria
that encompass representative drugs prescribed in
a European context.16 25e27 Future studies should also
focus on the clinical context of prescribing, linking the
clinical indication to the drug prescribed. These studies
should also incorporate follow-up details that relate to
important patient-centred outcomes such as quality of
life and self-reported adverse effects.
This analysis should be viewed as a screening study that
highlights potential problems and avoidable conse-
quences of PIMs, for instance, diminished quality of life
and admission to hospital as a consequence of an
adverse drug reaction. All prescribing decisions have
an element of risk and benefit and what may be classified
as a PIM may actually be in the patient’s best interest in
some circumstances. However the high level of use of
PIMs and the consistent pattern emerging from this and
other studies show that an almost inevitable conse-
quence of polypharmacy in an individual patient is likely
to be the prescription of a PIM.19 Further research is
needed to develop European-specific prescribing indi-
cators that link to important patient outcomes in terms
of quality of life and avoidance of adverse drug reactions.
Implications for practice and future research
Adverse drug reactions in older patients are recognised as
a substantial cause of preventable illness and features as
a priority for health research in terms of improving
patient care into the 21st century. With an ageing popu-
lation that is at increasing risk of developing multiple
morbidities as they grow older, a strategy is needed to
screen and select those individuals at greatest risk of
adverse drug reactions. It seems that age alone is not
likely to be an independent risk factor: multiple
morbidity requiring polypharmacy is emerging as the
single largest factor associated with PIMs with a conse-
quent risk of adverse drug reactions.28 Utilising strategies
to enhance suitable point of care prescribing in hospital
and community settings, and alerting prescribers to the
risk of PIMs either through computerised decision
support systems, education and training programmes or
the enhanced role of pharmacists to support improve-
ments in the quality of prescribing are initiatives that will
require ongoing investment and assessment.29
CONCLUSION
This population-based study shows that older patients
continue to receive high levels of PIMs. Polypharmacy
emerges as a consistent risk factor associated with such
medicines. Further research is needed to ensure a coor-
dinated approach, at the policy and individual level, so
that PIMs in older patients can be avoided and
contained.
Acknowledgements The authors thank Alison Bell and Duncan Heather of
the Health Informatics Centre, University of Dundee, for anonymisation,
record linkage and other procedural assistance in preparing the dataset;
Peter Donnan, Bruce Guthrie, Dougie McPhail, Marie Pitkethley, Clare
Stubbings and Frank Sullivan for advice throughout the project in their roles
as steering group members.
Funding EastRen Project Grant 141-07, Scottish School of Primary Care,
Mackenzie Building, University of Dundee, Kirsty Semple Way, Dundee, DD2
4BF.
Competing interests None.
Ethics approval This study was conducted with the approval of the Tayside
Research Ethics Committee.
Contributors All authors were responsible for initiating the research and
writing the study protocol. CM and KB performed the statistical analysis. TF,
KB and CM wrote the first draft of the paper and all authors were involved with
commenting on subsequent drafts of the paper. CM is the guarantor.
Provenance and peer review Not commissioned; externally peer reviewed.
280 BMJ Qual Saf 2011;20:275e281. doi:10.1136/bmjqs.2009.039818
Error management
REFERENCES
1. Avorn J, Shrank WH. Adverse drug reactions in elderly people:
a substantial cause of preventable illness. BMJ 2008;336:956e7.
2. Milton JC, Hill-Smith I, Jackson SH. Prescribing for older people. BMJ
2008;336:606e9.
3. Kavanagh S, Knapp M, Kavanagh S, et al. Primary care
arrangements for elderly people in residential and nursing homes
[comment]. BMJ 1999;318:666.
4. Goulding MR, Goulding MR. Inappropriate medication prescribing for
elderly ambulatory care patients. Arch Intern Med 2004;164:305e12.
5. Elder NC, Dovey SM, Elder NC, et al. Classification of medical errors
and preventable adverse events in primary care: a synthesis of the
literature. J Fam Pract 2002;51:927e32 [Erratum appears in J Fam
Pract. 2002 Dec;51(12):1079].
6. Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people:
the prescribing cascade. BMJ 1997;315:1096e9.
7. Stern MC, Jagger C, Clarke M, et al. Residential care for elderly
people: a decade of change [see comment]. BMJ 1993;306:827e30.
8. McMurdo ME, WithamMD, McMurdo MET, et al. Health and welfare of
older people in care homes [see comment]. BMJ 2007;334:913e14.
9. Walley T, Scott AK, Walley T, et al. Prescribing in the elderly.
Postgrad Med J 1995;71:466e71.
10. Black D, Bowman C, Black D, et al. Community institutional care for
frail elderly people.[see comment]. BMJ 1997;315:441e2.
11. Kavanagh S, Knapp M, Kavanagh S, et al. The impact on general
practitioners of the changing balance of care for elderly people living
in institutions [see comment]. BMJ 1998;317:322e7.
12. McGrath AM, Jackson GA, McGrath AM, et al. Survey of neuroleptic
prescribing in residents of nursing homes in Glasgow [see comment].
BMJ 1996;312:611e12.
13. Fahey T, Montgomery AA, Barnes J, et al. Quality of care for elderly
residents in nursing homes and elderly people living at home:
controlled observational study. BMJ 2003;326:580.
14. Donnan PT, Wei L, Steinke DT, et al. Presence of bacteriuria caused
by trimethoprim resistant bacteria in patients prescribed antibiotics:
multilevel model with practice and individual patient data [see
comment]. BMJ 2004;328:1297.
15. Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for
potentially inappropriate medication use in older adults: results of a US
consensus panel of experts. Arch Intern Med 2003;163:2716e24.
16. Spinewine A, Schmader KE, Barber N, et al. Appropriate prescribing
in elderly people: how well can it be measured and optimised? Lancet
2007;370:173e84.
17. De Wilde S, Carey IM, Harris T, et al. Trends in potentially
inappropriate prescribing amongst older UK primary care patients.
Pharmacoepidemiol Drug Saf 2007;16:658e67.
18. Gallagher P, Barry P, O’Mahony D, et al. Inappropriate prescribing in
the elderly. J Clin Pharm Ther 2007;32:113e21.
19. Carey IM, de Wilde S, Harris T, et al. What factors predict potentially
inappropriate primary care prescribing in older people? Drugs Aging
2008;25:693e706.
20. Perri M 3rd, Menon AM, Deshpande AD, et al. Adverse outcomes
associated with inappropriate drug use in nursing homes. Ann
Pharmacother 2005;39:405e11.
21. Lau DT, Kasper JD, Potter DE, et al. Hospitalization and death
associated with potentially inappropriate medication prescriptions
among elderly nursing home residents. Arch Intern Med
2005;165:68e74.
22. Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for
potentially inappropriate medication use in older adults: results of
a US consensus panel of experts [see comment]. Arch Intern Med
2003;163:2716e24. [Erratum appears in Arch Intern Med. 2004 Feb
9;164(3):298].
23. Gallagher PF, Barry PJ, Ryan C, et al. Inappropriate prescribing in an
acutely ill population of elderly patients as determined by Beers’
criteria. Age Ageing 2008;37:96e101.
24. Gurwitz JH, Field TS, Harrold LR, et al. Incidence and
preventability of adverse drug events among older persons in
the ambulatory setting [see comment]. JAMA 2003;
289:1107e16.
25. Gallagher P, Ryan C, Byrne S, et al. (Screening tool of older person’s
prescriptions) and START (Screening Tool To Alert Doctors To Right
Treatment). Consensus validation. Int J Clin Pharmacol Ther
2008;46:72e83.
26. Ryan C, O’Mahony D, Kennedy J, et al. Potentially inappropriate
prescribing in an Irish elderly population in primary care. Br J Clin
Pharmacol 2009;68:936e47.
27. Rognstad S, Brekke M, Fetveit A, et al. The Norwegian General
Practice (NORGEP) criteria for assessing potentially inappropriate
prescriptions to elderly patients. A modified Delphi study. Scand J
Prim Health Care 2009;27:153e9.
28. Zhang M, Holman CD, Price SD, et al. Comorbidity and repeat
admission to hospital for adverse drug reactions in older adults:
retrospective cohort study. BMJ 2009;338:a2752.
29. Spinewine A. Adverse drug reactions in elderly people: the challenge
of safer prescribing. BMJ 2008;336:956e7.
BMJ Qual Saf 2011;20:275e281. doi:10.1136/bmjqs.2009.039818 281
Error management
